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Abstracts / International Journal of Surgery 36 (2016) S31eS132S54Background: The National Institute of Clinical Excellence issued guide-
lines on Axillary Node Clearance (ANC) in patients with early and localised
primary breast cancer. A 2015 ABS Consensus statement explores how ANC
may be avoided. There is controversy in the management of patients with
low burden axillary disease as predicted from the Ultrasound (US) Scan.
Aim: To investigate the efﬁcacy of the US scan in identifying low burden
axillary disease in patients with primary breast cancer.
Method: A retrospective study was performed at a symptomatic breast
unit including all patients undergoing an ANC between January and
December 2014.
Result: A total of 112 patients had an ANC. All patients had an US Axilla.
72% had light burden disease on US scan (<3 nodes). 27 of these had 3 or
more positive nodes on ANC.
Conclusion: The majority of low burden disease identiﬁed from US scan
had a positive ANC. This suggests in symptomatic breast cancer that low
burden disease cannot always be predicted. Our current axillary man-
agement will be unchanged and we plan to conduct a prospective trial
having asked the radiologists to comment speciﬁcally on number of
involved nodes.http://dx.doi.org/10.1016/j.ijsu.2016.08.117
1256: ACCURACY OF INFORMATION ON SURGICAL MANAGEMENT OF
BREAST CANCER ON THE INTERNET
R. Waqar*, A. Oomman, N. Kirmani. Princess Alexandra Hospital, Harlow,
Essex, UK.
Aim: The aim of this study was to assess the accuracy and accessibility of
the information on the Surgical Management of Breast Cancer on the
internet.
Method: The contents of the top 100 websites from three different search
engines were selected. The quality of websites was evaluated using an
investigator-designed appraisal tool based on the guidelines from NICE,
Association of Breast Surgery and Good Surgical Practice.
Result: Reassuringly in 90% of the websites Surgical procedures like
‘Mastectomy’, ‘Breast conserving surgery’, ‘lymph node surgery’ and
‘breast reconstruction’ were discussed.Only 29% websites discussed
“Management of contralateral breast”.
Particular areas of weakness were the lack of information on management
of post-operative complications, surveillance and management of the
contralateral breast.
Conclusion: There appears to be a great variability in the quality of in-
formation present online on the surgical management of Breast cancer.
Grading of websites according to the accuracy of information they contain
may also enable healthcare professionals to signpost patients to trust-
worthy, up-to-date websites. There is an onus of the Royal College of
Surgeons and Surgical Associations to ensure that they invest in websites
that provide accurate information on the Surgical management of Breast
Cancer, so that nursing patients receive high quality information.http://dx.doi.org/10.1016/j.ijsu.2016.08.118Cardiothoracic surgery
0127: BLEEDING COMPLICATIONS IN AORTIC SURGERY WITH OR
WITHOUT APROTININ
A. Curtis 1,*, C. Rajakaruna 2. 1University of Bristol, Bristol, UK; 2Bristol Heart
Institute, Bristol, UK.
Aprotinin (Trasylol) may reduce bleeding complications in aortic surgery
but the evidence is limited and conﬂicting. There is also evidence that
aprotinin increases renal failure, stroke and mortality.
Aim: To determine whether aprotinin reduces bleeding complications in
adults undergoing aortic surgery.
Method: A single centre retrospective cohort study including 281
consecutive adult patients undergoing aortic surgery at the Bristol HeartInstitute. Of these, 105 (37.4%) received aprotinin and 176 (62.6%) did not.
The primary outcome was bleeding complication consisting of (i) post-
operative blood loss; (ii) transfusion requirements and (iii) haemoglobin
reduction. Secondary outcomes included systemic complications. Statis-
tical analysis was completed using the Mann Whitney U Test and Chi-
squared Test.
Result: Baseline characteristics and perioperative variables were similar
between the two groups. Total blood loss was only marginally lower
(p > 0.05) in the aprotinin group (750mL vs. 762.5mL) which didn't cause a
signiﬁcant difference in percentage haemoglobin reduction following
surgery (28.6% vs. 29.7%). There was also a non-signiﬁcant reduction in
blood product transfusions in the aprotinin group (52.4% vs. 59.1%).
Conclusion: This is the largest study to explore aprotinin use in aortic
surgery. Our results don't support the use of aprotinin in aortic surgery
with no signiﬁcant reduction in bleeding complications.http://dx.doi.org/10.1016/j.ijsu.2016.08.120
0172: MUCH ADO ABOUT NOTHING e ARE PATIENTS AWARE OF THE
MORTALITY DATA PUBLISHED BY THE SOCIETY OF CARDIOTHORACIC
SURGEONS?
J. Choi 1,*, R. Boix 2, J. Roxburgh 2, M. Sabetai 2. 1King's College London,
London, UK; 2Department of Cardiac Surgery, Guy's and St Thomas' NHS
Foundation Trust, London, UK.
Objective: Surgeon-speciﬁc mortality data (SSMD) in cardiac surgery
appeared in the public domain in 2007. However, there is no clear indi-
cation that the public appreciates or engages with these data. Our aimwas
to assess patient awareness and interpretation of the Society of Cardio-
thoracic Surgeons (SCTS) data on SSMD and hospital-speciﬁc mortality
data (HSMD).
Method: A questionnaire consisting of 17 questions, including SSMD and
HSMD published from 2010 to 2013 by the SCTS, was interpreted by 42
cardiac patients, 4 days post-operatively.
Result: No patients were aware of the HSMD and only 7% (3/42) of the
patients were aware of the SSMD published on the SCTS website. 83% (35/
42) of patients interpreted the SSMD correctly. Although these data only
mattered to 38%(16/42) of patients, 50% (21/42) would appreciate a dis-
cussion about the mortality data, prior to their operation.
Conclusion: Our study showed very little patient awareness of the SCTS
data. However, themajority of patients were able to interpret themortality
data and there was willingness to engage - patients care about results.
Therefore we pose the question e is it worth the SCTS investing in
increasing patient awareness or should we be using this data solely for
monitoring purposes?http://dx.doi.org/10.1016/j.ijsu.2016.08.121
0295: AORTIC REGURGITATION INCREASES WITH DURATION
FOLLOWING HEARTWARE HVAD IMPLANTATION
V. Naruka 2,*, S. Tsui 1, S. Pettit 1, C. Lewis 1. 1 Papworth Hospital NHS
Foundation Trust, Cambridge, UK; 2University of Cambridge and Papworth
Hospital NHS Foundation Trust, Cambridge, UK.
Aim: Patient survival and performance of continuous-ﬂow left ventricular
assist devices (CF LVAD) are adversely affected by aortic regurgitation (AR).
We examined the development of AR during HeartWare HVAD support.
Method: We reviewed records of 56 consecutive patients after HVAD
implantation between 2009 and 2015. Aortic valve (AV) opening was
encouraged by optimisation of LVAD speed and use of the Lavare cycle in
all patients.
Result: At LVAD implant: 2 patients required bioprosthetic AV
replacement (AVR); 12 had mild AR. During LVAD support: 18 patients
had no AR or resolution of mild AR. De novo mild AR developed in 22
patients. Moderate AR developed in 13 (10 de novo, 3 from pre-LVAD
mild AR). Severe AR developed in 2 (1 de novo, 1 from pre-LVAD mild
AR), both underwent urgent transplantation. Kaplan-Meier survival
